دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A decisive year for the neurological community
doi : 10.1016/S1474-4422(22)00001-1
Volume 21, Issue 2, February 2022, Page 103
Daridorexant for insomnia disorder
KaiSpiegelhalderaBerndFeigeaDieterRiemannaSimon DKyleb
doi : 10.1016/S1474-4422(22)00007-2
Volume 21, Issue 2, February 2022, Pages 104-105
From patients to disease: the difficult case of Alzheimer's
Giovanni BFrisoniaAurelienLathuilièrea
doi : 10.1016/S1474-4422(21)00461-0
Volume 21, Issue 2, February 2022, Pages 105-106
Frailty and outcome after traumatic brain injury
FrancescoPanzaaRodolfoSardoneaVittorioDibellobAntonioDanielecdVincenzoSolfrizzieMadiaLozuponef
doi : 10.1016/S1474-4422(21)00418-X
Volume 21, Issue 2, February 2022, Pages 107-108
Advancing research in autoimmune neuromuscular disorders
Donald BSandersa
doi : 10.1016/S1474-4422(21)00469-5
Volume 21, Issue 2, February 2022, Pages 108-110
Lightning progress in child neurology in the past 20 years
Ingrid EScheffera
doi : 10.1016/S1474-4422(22)00002-3
Volume 21, Issue 2, February 2022, Pages 111-113
Pimavanserin and dementia-related psychosis
Pierre NTariotabCliveBallardcDavangere PDevananddJeffrey LCummingsfDavid LSultzerf
doi : 10.1016/S1474-4422(21)00466-X
Volume 21, Issue 2, February 2022, Pages 114-115
The need for a better global dementia response
KatrinSeeheraRodrigoCataldiaNeerjaChowdharyaKavithaKolappaaTarunDuaa
doi : 10.1016/S1474-4422(21)00460-9
Volume 21, Issue 2, February 2022, Page 115
The need for a better global dementia response
LindsayWallaceaCarolBraynea
doi : 10.1016/S1474-4422(21)00459-2
Volume 21, Issue 2, February 2022, Pages 115-116
Primary stroke prevention: useful thresholds?
Valery LFeigina
doi : 10.1016/S1474-4422(21)00458-0
Volume 21, Issue 2, February 2022, Page 116
Guillain-Barré syndrome after vaccination against COVID-19
June YoungChunaSohyunParkbJongheonJungcSu-HyunKimdTae-SungKimbYoung JuChoiaHo JinKimdHyeon-SeokEomcJae-WonHyund
doi : 10.1016/S1474-4422(21)00416-6
Volume 21, Issue 2, February 2022, Pages 117-119
Correction to Lancet Neurol 2022; 21: 42–52
doi : 10.1016/S1474-4422(22)00006-0
Volume 21, Issue 2, February 2022, Page e2
Jeyaraj Pandian: passionate about improving stroke care in India
UdaniSamarasekera
doi : 10.1016/S1474-4422(21)00360-4
Volume 21, Issue 2, February 2022, Page 120
The Bell-Magendie debate
EmmanuelDrouinArnaudKwiatkowskiPatrickHautecoeur
doi : 10.1016/S1474-4422(22)00003-5
Volume 21, Issue 2, February 2022, Page 121
Social determinants of neurological disease: tackling inequalities
RuthDobsonCharlesMarshallAlastairNoyce
doi : 10.1016/S1474-4422(22)00005-9
Volume 21, Issue 2, February 2022, Pages 122-123
A neurological journey to save lives in HaitiAaron Berkowitz, One by One by One: Making a Small Difference Amid a Billion Problems, HarperOne (2020), p. 352, US $27·99, ISBN: 978-0-06-296421-2
Ernest JBarthélemy
doi : 10.1016/S1474-4422(21)00318-5
Volume 21, Issue 2, February 2022, Page 124
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
ProfEmmanuelMignotMDaDavidMaylebenPhDbProfIngoFietzeMDcdDamienLegerMDefGaryZammitPhDgClaudio L ABassettiMDhiScottPainMScjDalma SeboekKinterPhDkThomasRothPhDlinvestigators*
doi : 10.1016/S1474-4422(21)00436-1
Volume 21, Issue 2, February 2022, Pages 125-139
Variant-dependent heterogeneity in amyloid ? burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study
Jasmeer PChhatwalMDabcStephanie ASchultzPhDabEricMcDadeDOdAaron PSchultzPhDabLeiLiuMDacBernard JHanseeuwMDabiNellyJoseph-MathurinPhDeRebeccaFeldmanBSeColleen DFitzpatrickBSbcKathryn PSparksBAbProfJohannesLevinMDjknSarah BBermanMDlAlan ERentonPhDaaBianca TEspositoBSaaMaria VitoriaFernandezPhDfYun JuSungPhDfProfJae HongLeeMDpProfWilliam EKlunkMDlmAnnaHofmannMDoJames MNobleMDqProfNeillGraff-RadfordMDrProfHiroshiMoriPhDsProfSteven MSallowayMDuProfColin LMastersMDvwProfRalphMartinsPhDxCeleste MKarchPhDdProfChengjieXiongPhDgProfCarlosCruchagaPhDfRichard JPerrinMDhBrian AGordonPhDeProfTammie L SBenzingerMDeProfNick CFoxMDtProfPeter RSchofieldPhDyzProfAnne MFaganPhDdProfAlison MGoateDPhilaaProfJohn CMorrisMDdProfRandall JBatemanMDdProfKeith AJohnsonMDabcProfReisa ASperlingMDabcfor theDominantly Inherited Alzheimer's Network Investigators
doi : 10.1016/S1474-4422(21)00375-6
Volume 21, Issue 2, February 2022, Pages 140-152
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation
ProfStefaniaGalimbertiPhDabFrancescaGrazianoPhDabProfAndrew I RMaasPhDcGiuliaIserniaMDaProfFionaLeckyPhDdeSoniaJainPhDfXiaoyingSunPhDfRaquel CGardnerMDgSabrina RTaylorPhDhiAmy JMarkowitzJDhiProfGeoffrey TManleyPhDhiProfMaria GraziaValsecchiPhDabProfGiuseppeBellelliMDajProfGiuseppeCiterioMDak
doi : 10.1016/S1474-4422(21)00374-4
Volume 21, Issue 2, February 2022, Pages 153-162
Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders
Maartje GHuijbersPhDabAlexanderMarxMDcJaap JPlompPhDbRozenLe PansePhDdWilliam DPhillipsPhDe
doi : 10.1016/S1474-4422(21)00357-4
Volume 21, Issue 2, February 2022, Pages 163-175
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders
ProfAnna RostedtPungaPhDaPaulMaddisonMDbProfJeannine MHeckmannPhDcJeffrey TGuptillMDdAmeliaEvoliMDe
doi : 10.1016/S1474-4422(21)00297-0
Volume 21, Issue 2, February 2022, Pages 176-188
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders
ProfJan JGMVerschuurenMDaProfJacquelinePalaceMDbProfHiroyukiMuraiMDcMartijn RTannemaatMDaProfHenry JKaminskiMDdProfVeraBrilMDe
doi : 10.1016/S1474-4422(21)00463-4
Volume 21, Issue 2, February 2022, Pages 189-202
